Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment
A Penn Medicine study finds that semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment.
Adults receiving semaglutide for obesity treatment experienced greater improvements in several measures of disordered eating, eating disorder symptoms, and body image concerns compared with participants receiving placebo, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. The study was published today in the International Journal of Eating Disorders.
“Given the growing use of GLP-1 medications for obesity treatment, there has been interest in understanding how these therapies affect eating disordered behaviors and body image,” said Kelly Costello Allison, PhD, director of Penn’s Center for Weight and Eating Disorders (CWED) and the study's first author who presented findings of the study at ObesityWeek 2026 in Washington, D.C. “Our findings suggest that semaglutide not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss of control eating in many patients,” said Jena Tronieri, PhD, senior research investigator at Penn’s CWED and senior author of the study.
Improvements in eating behaviors and body image
The study included 120 adults seeking treatment for obesity. Participants were randomly assigned to receive either semaglutide 2.4 mg or placebo alongside a structured lifestyle intervention that included dietary counseling and physical activity guidance. Participants receiving semaglutide experienced substantially greater weight loss than those receiving placebo, losing an average of approximately 15 percent of their body weight after 60 weeks, compared with about 3 percent in the placebo group.
Over the course of the 60-week study, participants treated with semaglutide experienced significantly greater improvements in several measures of eating-related and psychological health compared with those receiving placebo. The medication was associated with larger reductions in loss-of-control eating, overall eating disorder psychopathology, and concerns related to body weight and shape. Participants in the semaglutide group also reported greater improvements in feelings of body dissatisfaction and body image.
Among individuals who entered the study with binge eating episodes or full or subthreshold binge-eating disorder, those receiving semaglutide were more likely to achieve remission and abstinence from binge eating behaviors. The emergence of new eating disorder symptoms and clinically meaningful worsening of eating-related psychopathology were uncommon in both treatment groups, suggesting that semaglutide treatment was generally associated with improvements, rather than deterioration, in eating-related outcomes.
The researchers noted that while average outcomes were favorable, a small number of participants experienced disordered eating behaviors during the study, underscoring the importance of continued monitoring, particularly among individuals with a history of eating disorders. The authors noted that larger studies will be needed to further evaluate the relationship between GLP-1 medications and eating disorders, particularly among individuals with diagnosed binge-eating disorder or a history of other eating disorders.
“These results are encouraging, particularly for patients who struggle with both obesity and binge eating,” said Allison. “At the same time, our findings highlight the importance of routinely assessing eating behaviors throughout treatment, particularly in patients with an eating disorder history, so that patients who develop concerning symptoms can receive appropriate care.”
Editor’s note: The study was funded in part through a research grant from the Novo Nordisk NNI Investigator Sponsored Studies Program. The sponsor played no role in the study's design, conduct, analysis, interpretation, or reporting.
Media contact
Matt Toal
C: 267-600-4871
Matthew.Toal@pennmedicine.upenn.edu
For Media Queries & Requests (24/7): 215-662-2560